Table 3.
Change in the functional state of the lower urinary tract in men with benign prostatic hyperplasia and taking solifenacin and tadalafil (n = 326).
| Groups |
Group A (N = 107) |
Group B (N = 107) |
Group C (N = 112) |
|||
|---|---|---|---|---|---|---|
| Observation period | Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment |
| Ultrasound examination | ||||||
| PV (mL) | 37.4 (4.8) | 35.2 (2.2) | 42.4 (6.4) | 41.0 (2.5) | 44.6 (5.1) | 44.2 (7.1) |
| I-PSS (in scores; some parameters) | ||||||
| Symptoms of obstruction | ||||||
| Incomplete emptying | 1.5 (0.5) | 1.1 (1.3) | 1.7 (0.2) | 1.6 (0.6) | 1.2 (0.3) | 1.4 (0.2) |
| Intermittence | 2.0 (0.3) | 1.8 (0.2) | 1.5 (0.6) | 1.4 (0.5) | 1.5 (1.1) | 1.4 (0.8) |
| Weak stream | 1.2 (0.4) | 1.1 (0.5) | 1.6 (0.6) | 1.1 (0.7) | 1.3 (0.7) | 1.3 (0.7) |
| Straining | 1.4 (0.4) | 1.3 (0.4) | 1.4 (0.7) | 1.5 (0.6) | 1.2 (0.4) | 1.3 (0.4) |
| Symptoms of hyperactivity | ||||||
| Urgency | 3.1 (0.8) | 1.5 (1.4) | 2.9 (0.7) | 1.1 (0.6)∗ | 2.5 (0.5) | 0.8 (0.6)∗ |
| Nocturia | 2.9 (1.2) | 1.3 (0.7) | 2.7 (1.0) | 0.7 (0.5)∗ | 2.8 (0.6) | 1.0 (0.5)∗ |
| OABq-SF (in scores; some parameters) | ||||||
| Urgency | 3.9 (1.2) | 3.1 (1.0) | 3.6 (0.9) | 1.4 (0.7)∗ | 4.2 (1.3) | 1.7 (0.8)∗ |
| Urgency incontinence | 0.4 (0.5) | 0.2 (0.2) | 1.0 (0.6) | 0.3 (0.3) | 0.5 (0.1) | 0.5 (0.4) |
| Nighttime frequency | 4.1 (0.9) | 2.3 (1.3) | 4.6 (1.2) | 1.5 (1.4)∗ | 3.9 (1.3) | 1.9 (0.5)∗ |
| Diaries of urination (the number of episodes/d) | ||||||
| Urgency | 1.8 (0.9) | 1.5 (0.5) | 1.7 (0.2) | 1.0 (0.3)∗ | 1.9 (0.3) | 0.9 (0.5)∗ |
| Daytime frequency | 8.3 (0.7) | 6.3 (1.0)∗ | 8.8 (1.4) | 5.4 (1.2)∗ | 7.9 (1.2) | 4.6 (0.9)∗ |
| Nighttime frequency | 2.0 (1.5) | 1.7 (0.8) | 2.3 (0.7) | 0.5 (0.5)∗ | 2.4 (0.9) | 0.5 (0.4)∗ |
| Episodes of incontinence | 0.3 (0.3) | 0.2 (0.1) | 0.6 (0.4) | 0.3 (0.1) | 0.6 (0.2) | 0.1 (0.05)∗ |
| Urodynamic parameters (uroflowmetry) | ||||||
| PVR (mL) | 33.5 (15.8) | 23.4 (7.2) | 40.2 (13.4) | 13.8 (9.4)∗ | 39.3 (12.3) | 14.1 (8.6)∗ |
| Qaver (mL/sec) | 15.2 (4.5) | 19.7 (3.4) | 14.2 (2.1) | 18.4 (1.6) | 12.9 (2.7) | 17.1 (2.1) |
| Qmax (mL/sec) | 18.7 (5.4) | 22.0 (2.1) | 17.0 (3.6) | 19.4 (3.6) | 18.6 (2.1) | 23.8 (1.9) |
SD is indicated in parentheses; significance of differences in the same group before and after treatment is denoted as ∗(P ≤ 0.05).
I-PSS, International Prostate Symptom Score; OABq-SF, Overactive Bladder Questionnaire—short form; PV, prostate volume; PVR, post void residual urine volume; Qaver, average flow rate; Qmax, maximum flow rate; SD, standard deviation.